levrett.com Report : Visit Site

Technical data of the levrett.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host levrett.com. Currently, hosted in United Kingdom and its service provider is United Hosting IPv4 Assignment .

the related websites

lse.co.uk digitallook.com whitman-howard.com livecharts.co.uk iii.co.uk hl.co.uk andor.com andor.co.uk jelldragon.com emccd.com ccd.com zoeharcombe.com gaugemaster.com 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Apache containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

image/svg+xml about directors news investors contact about directors news investors contact about directors news investors contact about plc is a special purpose acquisition company formed to acquire realisable and/or developed commercial technologies focused in the pharmaceutical and biotechnology sector. the company draws on its expertise in the pharmaceutical and biotechnology sector to assess different propositions and initiate discussions via market contacts and professional advisers. in selecting acquisition opportunities to review, the board will focus on entities that are available at attractive valuations and hold opportunities to unlock embedded value. once an acquisition target has been identified the company will carry out a comprehensive and thorough project review process in which all material aspects of a potential project or business will be subject to rigorous due diligence, as appropriate. opportunities meeting the following criteria would be eligible for further evaluation: fit within the focus area of the pharmaceutical and biotechnology sector sustainable technological advantage above average business potential sound intellectual property protection or potential for patenting clearly definable milestones for development scientists commitment and dedication foreseeable exit potential evaluation criteria will include: in-house expertise peer-reviewed literature investigating other companies developing related technologies consulting clinicians identifying competitors understanding the competitive eco system balancing the clinical science and commercialisation skills of management following completion of an acquisition, the objective will be to operate the acquired business and implement an operating strategy with a view to generating value for its shareholders through operational and product development as well as possible complimentary acquisitions. we believe that the uk and eu have a strong pool of potentially suitable acquisition targets that are currently undervalued or require further investment to reach profitability. the board has significant expertise in: working in the biotechnology sector recognising and commercialising key developments in the sector financing and developing businesses investing in early stage opportunities directors professor john lidgey, non-executive chairman professor lidgey, is currently emeritus professor of electronic engineering at oxford brookes university. having completed his phd at the university of surrey in 1973 and after four years at the university of newcastle, nsw, australia returned to england in 1978 to join oxford polytechnic, which became oxford brookes university in 1992. he remained at oxford brookes university becoming professor of electronic engineering and assistant dean in the school of technology. during this period he has gained significant international recognition for system design with applications covering many sectors including bio-medical electronics and diagnostic instrumentation. pascal hughes, chief executive officer mr hughes is a financier, investor and entrepreneur. he previously worked in investment banking in the city of london for close to 20 years most recently as a managing director in fixed income, currencies and commodities at ubs bank. prior to that he was a managing director in global banking and markets at hsbc. he left ubs to become an active private investor and advisor to start-up companies in a variety of different business areas from financial technologies to oil field services. during this period he has been involved in developing businesses and advising on acquisition and turn round strategy. pascal has a b.a (hons) in accounting and finance from dublin city university, and an msc. in financial economics from queens university belfast. tony reeves, non-executive director tony reeves has over 45 years’ public company experience in europe, usa and the middle east. he is the non-executive chairman of cloudtag inc, an aim listed technology firm that is focused on bringing medical quality devices to the fitness market. he also holds the position as non-executive chairman of kellan group plc, the aim listed recruitment business, and prior to this, he was chairman and chief executive officer of the hotgroup plc until its acquisition in 2005. previously, he was chairman and chief executive officer of the delphi group plc until 2001 when it was acquired by adecco sa. before joining delphi group plc, tony was chairman, president and chief executive officer of lifetime corporation, a recruitment agency staffing hospitals and construction projects primarily in the middle east. he oversaw lifetime reverse into a company listed on the american stock exchange in 1986 with revenues of $25 million, which grew to $1 billion in 1993. tony oversaw the sell of lifetime to olsten for $660 million. news nuformix rns announcement – cancellation of share listing following a reverse takeover on the london stock exchange’s market for regulated securities the undermentioned securities nuformix plc (formerly plc: named changed 13 october 2017) will be cancelled from 16 october 2017 8.00 a.m. full announcement here notice of admission to trading on the official list and to trading on the london stock exchange’s market for regulated securities following a reverse takeover on the london stock exchange’s market for regulated securities the undermentioned securities nuformix plc (formerly plc: named changed 13 october 2017) will this morning be admitted to the standard segment of the official list and are expected to commence trading on the london stock exchange’s main market for listed securities this morning, 16 october 2017, at 8.00 a.m. ticker: nfx nuformix admission rns 16.10.17 13/10/2017 – the company announces that today the name of the company has been changed from plc to nuformix plc. , a company formed to acquire a target company with realisable or developed commercial technologies in the pharmaceutical and biotechnology sector, announces that today the name of the company has been changed from plc to nuformix plc. full report here 13/10/2017 – gm results and completion of acquisition of nuformix limited , a company formed to acquire a target company with realisable or developed commercial technologies in the pharmaceutical and biotechnology sector, announces its gm results and completion of acquisition of nuformix limited. full report can be found here. gm results and completion of acquisition of nuformix limited 13/10/2017 – interim results , a company formed to acquire a target company with realisable or developed commercial technologies in the pharmaceutical and biotechnology sector, announces its interim results for the period ended 30 september 2017. full report can be found here. plc interim results 22/09/17 – final results for the year ended 31 march 2017 click here to read the full report 15/09/17 – proposed acquisition of nuformix limited, placing of new ordinary shares, approval of a waiver of obligation under rule 9 of the city code on takeovers and mergers, notice of general meeting and publishing and posting of the prospectus plc, a company formed to acquire a target company in the pharmaceutical and biotechnology sector, is pleased to announce that it has entered into a conditional agreement to acquire the entire issued share capital of nuformix limited (“nuformix”) for a total consideration of £12,000,000 to be settled through the issuance of new ordinary shares in the company at a price of 4 pence per share (the “acquisition”), subject to shareholders’ approval and re-admission (as defined below). in addition, the company is today announcing the placing, under which it has issued 57,500,000 placing shares at 4p per share, raising £2.3 million, conditional, inter alia, upon re-admission. click here to read the full report 23/12/16 – interim results , a company formed to acquire a target company with realisable or developed commercial technologies in t

URL analysis for levrett.com

http://www.levrett.com/investors
http://www.levrett.com/contact
http://www.levrett.com/directors
http://www.levrett.com/about
http://www.levrett.com/news

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: LEVRETT.COM
Registry Domain ID: 1873268031_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.enom.com
Registrar URL: http://www.enom.com
Updated Date: 2017-08-16T15:55:48Z
Creation Date: 2014-08-29T08:31:45Z
Registry Expiry Date: 2018-08-29T08:31:45Z
Registrar: eNom, Inc.
Registrar IANA ID: 48
Registrar Abuse Contact Email:
Registrar Abuse Contact Phone:
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: NS1.RUBY.BMAS.AGENCY
Name Server: NS2.TIGER.BMAS.AGENCY
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-09-26T00:45:12Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR eNom, Inc.

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =levrett.com

  PORT 43

  TYPE domain

DOMAIN

  NAME levrett.com

  CHANGED 2017-08-16

  CREATED 2014-08-29

STATUS
clientTransferProhibited https://icann.org/epp#clientTransferProhibited

NSERVER

  NS1.RUBY.BMAS.AGENCY 212.113.132.216

  NS2.TIGER.BMAS.AGENCY 212.113.135.119

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .